Coronary Artery Disease Clinical Trial
— ORACLEOfficial title:
ORACLE: Objective Risk Assessment in Patients With Possible Anginal Chest Pain Using Leading Technology
The ORACLE study is an observational cohort study designed to explore the feasibility of providing an assessment of chest pain for patients with suspected angina within one working day of referral to specialist services. The primary objective is to determine the feasibility of delivering an objective assessment of risk for participants who have been referred by their primary care provider to the rapid access chest pain clinic with possible angina in a community setting using point of care and patient facing technologies within one working day of referral. Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms. Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured by point of care high sensitivity cardiac troponin assays as well as a core lab assay. The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events.
Status | Not yet recruiting |
Enrollment | 300 |
Est. completion date | February 28, 2025 |
Est. primary completion date | November 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years and older |
Eligibility | Inclusion Criteria: - >30 years of age - Referral to the rapid access chest pain clinic with possible new onset or worsening angina Exclusion Criteria: - Inability to give informed consent. - Previous recruitment to the study. - Acute coronary syndrome within 3 months. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Edinburgh |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Proportion of participants reclassified as low, intermediate, or high risk using standard laboratory assays compared to point-of-care high-sensitivity cardiac troponin assay. | Patients will have a point of care troponin and a core laboratory high sensitivity troponin. The proportion of patients who are re-classified by the current laboratory clinical standard will be recorded | This will be completed during the patients study visit, anticipated to last 1 hour | |
Other | Proportion of participants reclassified as low, intermediate, or high risk using standard 12-lead compared to personal 12-lead electrocardiography | Patients will have a standard 12 lead and personal ECG. The proportion of patients who are re-classified by the current clinical standard 12 lead ECG will be recorded. | This will be completed during the patients study visit, anticipated to last 1 hour | |
Primary | Proportion of participants in whom a chest pain risk assessment is complete within one working day of referral. | The proportion of participants who have been referred by their primary care provider to the rapid access chest pain clinic with possible angina in whom a complete risk assessment is delivered in a community setting using point of care and patient facing technologies within one working day of referral. | This is the time from referral to rapid access chest pain clinic through to completion of their visit, anticipated to be between 1 and 3 days. | |
Secondary | Proportion of patients who can have their risk assessment completed in one, two or three or more working days from referral to service until completion of risk assessment. | The proportion of participants who have been referred by their primary care provider to the rapid access chest pain clinic with possible angina in whom a complete risk assessment is delivered in a community setting using point of care and patient facing technologies within one, two or three or more working days of referral. | This is the time from referral to rapid access chest pain clinic through to completion of their visit, anticipated to be between 1 and 3 days. | |
Secondary | Proportion of valid and interpretable point-of-care troponin tests | This will be the proportion of patients in whom a valid high sensitivity cardiac troponin result can be obtained from undertaking the point of care assay. | This will be completed during the patients study visit, anticipated to last 1 hour | |
Secondary | Proportion of personal electrocardiograms that are interpretable | This will be the proportion of patients in whom an interpretable personal ECG has been performed | This will be completed during the patients study visit, anticipated to last 1 hour | |
Secondary | Proportion of participants stratified as low, intermediate, or high risk using objective risk stratification. | This will be the proportion of patients who are stratified into low, intermediate or high risk groups on completion of their risk assessment. | This will be completed during the patients study visit, anticipated to last 1 hour | |
Secondary | Proportion of participants with and without a clinical diagnosis of angina stratified as low, intermediate, or high risk and according to triage status. | This will be the proportion of patients who do and do not receive a clinical diagnosis of angina and this will be stratified by triage status | This will be obtained at 3 months following completion of the patient's assessment. | |
Secondary | Proportion of participants with unscheduled Emergency Department attendance(s) at 3 months stratified as low, intermediate, or high risk and according to triage status. | This will be the proportion of patients who present acutely to the emergency department in the 3 months following assessment. This will be stratified by risk stratification and their clinical triage status. | This will be obtained at 3 months following completion of the patient's assessment. | |
Secondary | Proportion of participants with cardiac death or non-fatal myocardial infarction at 3 months stratified as low, intermediate, or high risk and according to triage. | This will be the proportion of patients who have cardiac death or fatal myocardial infarction in the 3 months following assessment. This will be stratified by risk stratification and their clinical triage status. | This will be obtained at 3 months following completion of the patient's assessment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |